BIOCRYST PHARMACTL earnings per share and revenue

BO1 earnings per share for the last quarter are -0.15 CHF whereas the estimation was -0.19 CHF which accounts for 18.80% surprise. Company revenue for the same period amounts to 83.68 M CHF despite the estimated figure of 77.24 M CHF. Estimated earnings per share for the next quarter are -0.16 CHF, and revenue is expected to reach 89.38 M CHF. Also watch annual changes over time to get a bigger picture of BO1 earnings per share and revenue dynamics.